Literature DB >> 6602609

Differences in deoxycytidine metabolism in mouse and rat.

T S Chan, B D Lakhchaura, T F Hsu.   

Abstract

Bone-marrow macrophages from both rat and mouse release deoxycytidine derived from phagocytosed nuclei. Mouse plasma contains no detectable deoxycytidine (less than 0.1 microM), whereas the concentration in rat plasma is 18 microM. Enzyme assays of tissue extracts show that both mouse and rat spleen contain high deoxycytidine kinase activity. Mouse organs, including kidney, liver and lung, also have deoxycytidine deaminase activity. In contrast, rat tissues have virtually no deoxycytidine deaminase activity. Lack of deaminase provides an explanation for the presence of deoxycytidine in rat plasma. Cytotoxicity assays show that cultured mouse lymphoid cells grown in undialysed rat serum are more resistant to cytotoxic effects of deoxyadenosine than are those cells grown in dialysed rat serum. The results suggest that a major difference in deoxycytidine metabolism between mouse and rat may account for discrepancies in the pharmacological response of the two animals to certain nucleoside compounds.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602609      PMCID: PMC1154233          DOI: 10.1042/bj2100367

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  15 in total

1.  A human-mouse somatic hybrid line selected for human deoxycytidine deaminase.

Authors:  T S Chan; C Long; H Green
Journal:  Somatic Cell Genet       Date:  1975-01

2.  Evaluation of microparticle chemically bonded reversed-phase packings in the high-pressure liquid chromatographic analysis of nucleosides and their bases.

Authors:  R A Hartwick; P R Brown
Journal:  J Chromatogr       Date:  1976-11-03

3.  Deoxyguanosine toxicity on lymphoid cells as a cause for immunosuppression in purine nucleoside phosphorylase deficiency.

Authors:  T S Chan
Journal:  Cell       Date:  1978-07       Impact factor: 41.582

4.  Alterations leading to increased ribonucleotide reductase in cells selected for resistance to deoxynucleosides.

Authors:  M Meuth; H Green
Journal:  Cell       Date:  1974-12       Impact factor: 41.582

5.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

6.  Comparative study of nuclear expulsion from the late erythroblast and cytokinesis.

Authors:  E Skutelsky; D Danon
Journal:  Exp Cell Res       Date:  1970-06       Impact factor: 3.905

7.  Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease.

Authors:  J Donofrio; M S Coleman; J J Hutton; A Daoud; B Lampkin; J Dyminski
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

8.  Purine excretion by mouse peritoneal macrophages lacking adenosine deaminase activity.

Authors:  T S Chan
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

9.  Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.

Authors:  G L Neil; T E Moxley; R C Manak
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

10.  Pyrimidine excretion by cultured fibroblasts: effect of mutational deficiency in pyrimidine salvage enzymes.

Authors:  T S Chan; M Meuth; H Green
Journal:  J Cell Physiol       Date:  1974-04       Impact factor: 6.384

View more
  6 in total

1.  Changes in 2'-deoxycytidine levels in various tissues of tumor-bearing mice.

Authors:  Ayano Iwazaki; Kimie Imai; Kunio Nakanishi; Masanori Yoshioka
Journal:  Oncol Lett       Date:  2010-09-08       Impact factor: 2.967

2.  A rat model of purine nucleoside phosphorylase deficiency.

Authors:  W R Osborne; R W Barton
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

3.  Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma.

Authors:  J T Eells; R Spector
Journal:  Neurochem Res       Date:  1983-11       Impact factor: 3.996

Review 4.  New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.

Authors:  V W Ruiz van Haperen; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

5.  Radiation metabolomics. 2. Dose- and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal gamma-radiation exposure in mice.

Authors:  John B Tyburski; Andrew D Patterson; Kristopher W Krausz; Josef Slavík; Albert J Fornace; Frank J Gonzalez; Jeffrey R Idle
Journal:  Radiat Res       Date:  2009-07       Impact factor: 2.841

6.  Metabolic Fingerprinting in Toxicological Assessment Using FT-ICR MS.

Authors:  Mina Hasegawa; Mika Ide; Mitsuru Kuwamura; Jyoji Yamate; Shigeo Takenaka
Journal:  J Toxicol Pathol       Date:  2010-06-30       Impact factor: 1.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.